On Thursday, RBC Capital maintained its optimistic stance on Arrowhead Pharmaceuticals (NASDAQ:ARWR), reiterating an Outperform rating with a steadfast $50.00 price target on the company's stock. The firm's analysis follows a recent non-deal roadshow in Boston where Arrowhead's CEO portrayed confidence in the company's cardiometabolic and muscle programs.
The CEO highlighted the anticipation for forthcoming data on familial chylomicronemia syndrome (FCS) and the potential market differentiation compared to competitors like Ionis Pharmaceuticals (NASDAQ:IONS). Additionally, the CEO expressed enthusiasm for Arrowhead's first-in-human studies for INHBE gene in obesity treatment.
The CEO's assurance was particularly strong on the company's myotonic dystrophy type 1 (DM1) program, citing advantages such as transferrin-sparing and lower dosages compared to rivals RNA and Dyne Therapeutics.
However, the tone was more cautious concerning the pulmonary segment, noting the absence of fixed timelines for fractional exhaled nitric oxide (FeNO) data and the possibility that a partnership might be necessary to advance the asthma program.
Regarding financial strategies, the CEO indicated that Arrowhead is considering various options, including risk-sharing debt instruments. RBC Capital's analyst emphasized that Arrowhead's current market valuation does not align with that of peers such as Alnylam Pharmaceuticals or Ionis, let alone RNA or Dyne Therapeutics.
The firm's stance is that the market is undervaluing Arrowhead's robust pipeline, which strategically balances well-established liver targets with high-potential, higher-risk extrahepatic assets. RBC Capital's position encourages investors to buy, underlining the potential growth based on Arrowhead's diverse and promising pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.